A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Foghorn Therapeutics Inc.
FHTX
$266M
Mkt Cap
$4.85
-4.34%
Foghorn Therapeutics Inc. (FHTX) has a 5-year average return on invested capital (ROIC) of -45.5%. This is below average and may indicate limited pricing power.
Foghorn Therapeutics Inc. (FHTX) has a market capitalization of $274M. It is classified as a small-cap stock.
Foghorn Therapeutics Inc. (FHTX) does not currently pay a regular dividend.
Foghorn Therapeutics Inc. (FHTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Foghorn Therapeutics Inc. (FHTX) generated $-101 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Foghorn Therapeutics Inc. (FHTX) reported earnings per share (EPS) of $-1.58 in its most recent fiscal year.
The Ledger Terminal provides 5 years of financial data for Foghorn Therapeutics Inc. (FHTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation. The chromatin regulatory system orchestrates gene expression—the turning on and off of genes—which is fundamental to how all our cells function. The chromatin regulatory system is implicated in approximately 50 percent of all cancers, and understanding how this system works could lead to an entirely new class of precision medicines. To our knowledge, we are the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 25M | - | - | - | - | - |
| Net Income | -72M | -87M | -98M | -109M | -101M | -69M |
| EPS | $-1.14 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-6.23 |
| Free Cash Flow | -89M | -101M | -119M | 192M | -54M | -47M |
| ROIC | -33.3% | -28.6% | -29.8% | -82623.4% | -82.2% | -41.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -7.24 | -4.70 | 3,614.03 | 4.37 | 0.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -87M | -103M | -108M | -117M | -101M | -69M |
| Operating Margin | -352.9% | - | - | - | - | - |
| ROE | 0.0% | - | - | -97216.1% | -104.6% | -47.1% |
| Shares Outstanding | 57M | 55M | 42M | 42M | 37M | 41M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 25M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -69M | -101M | -117M | -108M | -103M | -87M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -352.9% |
| Net Income | -69M | -101M | -109M | -98M | -87M | -72M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -294.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -41.5% | -82.2% | N/M | -29.8% | -28.6% | -33.3% |
| ROE | -47.1% | -104.6% | -97216.1% | N/A | N/A | 0.0% |
| ROA | -26.9% | -19.5% | -26.9% | -34.4% | -30.4% | -35.2% |
| Cash Flow | ||||||
| Op. Cash Flow | -31M | -50M | 194M | -118M | -100M | -88M |
| Free Cash Flow | -47M | -54M | 192M | -119M | -101M | -89M |
| Owner Earnings | -33M | -53M | 176M | -138M | -115M | -103M |
| CapEx | 16M | 3.3M | 1.2M | 1.2M | 906K | 0 |
| Maint. CapEx | 1.3M | 3.2M | 3.3M | 3.5M | 3.1M | 3.1M |
| Growth CapEx | 15M | 86K | 0 | 0 | 0 | 0 |
| D&A | 1.3M | 3.2M | 3.3M | 3.5M | 3.1M | 3.1M |
| CapEx/OCF | N/A | N/A | 0.6% | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | 14M | 16M | 12M | 12M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -73M | N/A | N/A | N/A | N/A | -89M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 89M |
| Long-Term Debt | 20M | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.13 | 4.37 | 3614.03 | -4.70 | -7.24 | 0.00 |
| Interest Coverage | -70.0 | -52.9 | N/A | N/A | N/A | N/A |
| Equity | 146M | 97M | 112K | -77M | -46M | -90M |
| Total Assets | 256M | 520M | 405M | 286M | 284M | 205M |
| Total Liabilities | 109M | 423M | 405M | 363M | 330M | 295M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -163M | -264M | -373M | -472M | -558M | -558M |
| Working Capital | 172M | 411M | 296M | 182M | 183M | 183M |
| Current Assets | 191M | 460M | 351M | 240M | 250M | 250M |
| Current Liabilities | 19M | 49M | 55M | 58M | 67M | 67M |
| Per Share Data | ||||||
| EPS | -6.23 | -2.73 | -2.62 | -2.34 | -1.58 | -1.14 |
| Owner EPS | -0.79 | -1.44 | 4.23 | -3.27 | -2.11 | -1.83 |
| Book Value | 3.53 | 2.61 | 0.00 | -1.84 | -0.83 | -1.59 |
| Cash Flow/Share | -0.76 | -1.35 | 4.66 | -2.81 | -1.83 | -1.22 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 41.4M | 37.1M | 41.6M | 42.1M | 54.8M | 56.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -4.3 |
| P/FCF | N/A | N/A | 1.2 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 6.4 | 7.8 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 11.2 |
| FCF Yield | -5.1% | -7.1% | 82.4% | -42.0% | -38.3% | -32.4% |
| Market Cap | 938M | 752M | 234M | 284M | 264M | 274M |
| Avg. Price | 19.02 | 13.18 | 11.95 | 6.38 | 6.54 | 4.85 |
| Year-End Price | 22.65 | 20.26 | 5.62 | 6.76 | 4.82 | 4.85 |
Foghorn Therapeutics Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -13.7%.
Foghorn Therapeutics Inc. (FHTX) has a book value per share of $-0.83, based on its most recent annual SEC filing.